1.      Abou Haidar L, Pachnis P, Gotway GK, Ni M, DeBerardinis RJ, McNutt MC. Partial N‐acetyl glutamate synthase deficiency presenting as postpartum hyperammonemia: Diagnosis and subsequent pregnancy management. JIMD Rep. Kasım 2023;64(6):403-9.

2.      Bélanger-Quintana A, Arrieta Blanco F, Barrio-Carreras D, Bergua Martínez A, Cañedo Villarroya E, García-Silva MT, vd. Recommendations for the Diagnosis and Therapeutic Management of Hyperammonaemia in Paediatric and Adult Patients. Nutrients. 02 Temmuz 2022;14(13):2755.

3.      British Inherited Metabolic Disease Group (BIMDG). Hyperammonaemia Management Guidelines [Internet]. United Kingdom: BIMDG; 2020 [cited 2023 Oct 15]. Available from: https://bimdg.org.uk/site/guidelines.asp

4.      Camacho, J., & Rioseco-Camacho, N. (2012). Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.

5.      ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT06255782, A Study of ECUR-506 in Participants With Ornithine Transcarbamylase (OTC) Deficiency (OTC-HOPE); 2024 Feb 12 [cited 2025 Nov 23]. Available from: https://clinicaltrials.gov/study/NCT06255782

6.      Das AM. Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy. Metab Brain Dis. 26 Nisan 2025;40(5):192.

7.      Duff C, Alexander IE, Baruteau J. Gene therapy for urea cycle defects: An update from historical perspectives to future prospects. J Inherit Metab Dis. Ocak 2024;47(1):50-62.

8.      Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, vd. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 29 Mayıs 2012;7:32.

9.      Häberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, vd. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. Kasım 2019;42(6):1192-230.

10.  Habib A, Mohamed Shakrin N. Hyperargininemia Due to Arginase 1 Deficiency: Variability in Clinical and Biochemical Presentations in Malaysian children. Clin Pathol. Ocak 2022;15:2632010X221093274.

11.  Ibrahim M, Gold J, Woodall A, Yilmaz B, Gissen P, Stepien K. Diagnostic and Management Issues in Patients with Late-Onset Ornithine Transcarbamylase Deficiency. Children. 09 Ağustos 2023;10(8):1368.

12.  Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition. World Health Organ Tech Rep Ser. 2007;(935):1-265, back cover. PMID: 18330140.

13.  Kido J, Matsumoto S, Häberle J, Nakajima Y, Wada Y, Mochizuki N, vd. Long‐term outcome of urea cycle disorders: Report from a nationwide study in Japan. J Inherit Metab Dis. Temmuz 2021;44(4):826-37.

14.  McNutt MC, Foreman N, Gotway G. Arginase 1 Deficiency in Patients Initially Diagnosed with Hereditary Spastic Paraplegia. Mov Disord Clin Pract. Ocak 2023;10(1):109-14.

15.  Moedas MF, Simões RJM, Silva MFB. Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies. Biochem Pharmacol. Nisan 2024;222:116034.

16.  Nagamani SCS, Erez A, Lee B. Argininosuccinate lyase deficiency. Genet Med. Mayıs 2012;14(5):501-7.

17.  National Institute for Health and Care Excellence (NICE). Pegzilarginase for treating arginase-1 deficiency in people 2 years and over [ID4029]: Draft guidance consultation [Internet]. London: NICE; 2025 Jun [cited 2025 Nov 23]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-hst10054/documents

18.  Ozturk K, McKinney AM, Nascene D. Urea Cycle Disorders: A Neuroimaging Pattern Approach Using Diffusion and FLAIR MRI. J Neuroimaging. Ocak 2021;31(1):144-50.

19.  Raina R, Bedoyan JK, Lichter-Konecki U, Jouvet P, Picca S, Mew NA, vd. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16(8):471-82.

20.  Ravindranath A, Sarma MS. Mitochondrial hepatopathy: Anticipated difficulties in management of fatty acid oxidation defects and urea cycle defects. World J Hepatol. 27 Ocak 2022;14(1):180-94.

21.  Redant S, Empain A, Mugisha A, Kamgang P, Attou R, Honoré PM, vd. Management of late onset urea cycle disorders—a remaining challenge for the intensivist? Ann Intensive Care. Aralık 2021;11(1):2.

22.  Ribas GS, Lopes FF, Deon M, Vargas CR. Hyperammonemia in Inherited Metabolic Diseases. Cell Mol Neurobiol. Kasım 2022;42(8):2593-610.

23.  Siri B, Greco B, Martinelli D, Cairoli S, Guarnera A, Longo D, vd. Positive Clinical, Neuropsychological, and Metabolic Impact of Liver Transplantation in Patients With Argininosuccinate Lyase Deficiency. J Inherit Metab Dis. Ocak 2025;48(1):e12843.

24.  Summar ML, Mew NA. Inborn Errors of Metabolism with Hyperammonemia. Pediatr Clin North Am. Nisan 2018;65(2):231-46.

25.  Vuković T, Kuek LE, Yu B, Makris G, Häberle J. The therapeutic landscape of citrin deficiency. J Inherit Metab Dis. Kasım 2024;47(6):1157-74.

26.  Ziogas IA, Wu WK, Matsuoka LK, Pai AK, Hafberg ET, Gillis LA, vd. Liver Transplantation in Children with Urea Cycle Disorders: The Importance of Minimizing Waiting Time. Liver Transpl. Aralık 2021;27(12):1799-810.